Figure 5. Effect of AK005401 on antioxidant capacity and target genes expressions. Mice and HT22 cells were used to establish I/R model and OGD/R model, respectively. The activities of CuZn SOD and GSH-Px and MDA level in tissue and cells were determined with spectrophotometrical method according to the procedure described by assay kit. (A1–A3) represent the activities of SOD and GSH-Px and MDA level in hippocampus tissue (n=10). (B1–B3) represent the activities of SOD and GSH-Px and MDA level in cells (n=8). Total RNA were isolated from vascular endotheliums and RAECs using Trizol (Invitrogen) according to the manufacturer’s instruction. cDNA was synthesized with PrimeScript reverse transcriptase (TaKaRa, Dalian, China) and oligo (dT) (20 bp) following the manufacturer’s instructions. Real-time PCR was performed using SYBR Premix Ex TaqTM II kit. Relative expressions of AK005401, YY1, FGF21, and CuZn SOD were calculated using the 2−ΔΔCT method on a real-time PCR system. (C1–C4) represent the expression levels of AK005401, YY1, FGF21, and CuZn SOD in hippocampus tissue, respectively. (D1–D4) represent the expression levels of AK005401, YY1, FGF21, and CuZn SOD in HT22 cells, respectively. Data were presented as mean±SD (n = 3). One-way ANOVA test was used to determine statistical significance. **P < 0.01 vs. normal group or control group, ##P < 0.01 vs. I/R group or OGD/R group.